INT50579

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1995
Last Reported 2010
Negated 7
Speculated 1
Reported most in Abstract
Documents 84
Total Number 85
Disease Relevance 17.52
Pain Relevance 17.45

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP3A4) oxidoreductase activity (CYP3A4) endoplasmic reticulum (CYP3A4)
enzyme binding (CYP3A4) lipid metabolic process (CYP3A4) cytoplasm (CYP3A4)
Anatomy Link Frequency
liver 9
plasma 6
blood 1
bile 1
optic 1
CYP3A4 (Homo sapiens)
Pain Link Frequency Relevance Heat
sSRI 64 100.00 Very High Very High Very High
fluoxetine 44 100.00 Very High Very High Very High
corticosteroid 4 100.00 Very High Very High Very High
Buprenorphine 415 99.98 Very High Very High Very High
lidocaine 61 99.96 Very High Very High Very High
carbamazepine 136 99.88 Very High Very High Very High
Opioid 115 99.76 Very High Very High Very High
antidepressant 61 99.60 Very High Very High Very High
methadone 51 99.28 Very High Very High Very High
Paracetamol 33 99.16 Very High Very High Very High
Disease Link Frequency Relevance Heat
Acquired Immune Deficiency Syndrome Or Hiv Infection 230 99.52 Very High Very High Very High
Cognitive Disorder 153 99.36 Very High Very High Very High
Reprotox - General 2 156 98.96 Very High Very High Very High
Sleep Disorders 40 98.40 Very High Very High Very High
Stress 25 98.32 Very High Very High Very High
Toxicity 264 98.28 Very High Very High Very High
Post Operative Pain 1 98.08 Very High Very High Very High
Nonarteritic Anterior Ischaemic Optic Neuropathy 16 97.84 Very High Very High Very High
Arteritic Anterior Ischaemic Optic Neuropathy 2 97.70 Very High Very High Very High
INFLAMMATION 77 97.20 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Alfentanil clearance is an excellent in vivo probe for hepatic CYP3A4 activity and drug interactions in humans.
CYP3A4 Binding (interactions) of
1) Confidence 0.48 Published 2001 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 11753266 Disease Relevance 0.16 Pain Relevance 0.38
The study of interactions of newly synthesized compounds with CYP3A4 has been incorporated into drug development and detection of possible CYP3A4 inhibitors and inducers during the early stages of drug development is critical in preventing potential drug-drug interactions and side effects.
CYP3A4 Binding (interactions) of
2) Confidence 0.48 Published 2008 Journal Curr. Drug Metab. Section Abstract Doc Link 18473749 Disease Relevance 0.22 Pain Relevance 0.13
A recent study indicates that CYP3A4 undergoes dramatic conformational changes upon binding to ketoconazole or erythromycin with a differential but substantial (>80%) increase in the active site volume, providing a structural basis for ligand promiscuity of CYP3A4.
CYP3A4 Binding (binding) of
3) Confidence 0.48 Published 2008 Journal Curr. Drug Metab. Section Abstract Doc Link 18473749 Disease Relevance 0.06 Pain Relevance 0
Ketoconazole, terfenadine, and astemizole were observed to inhibit amprenavir depletion, consistent with their known specificity for CYP3A4.
CYP3A4 Binding (specificity) of
4) Confidence 0.48 Published 1998 Journal J Pharm Sci Section Abstract Doc Link 9649346 Disease Relevance 0.19 Pain Relevance 0.09
Because doxycycline interacts with CYP3A4 enzymes, there is potential for drug interactions with a number of medications.
CYP3A4 Binding (interacts) of
5) Confidence 0.47 Published 2006 Journal Curr Treat Options Neurol Section Abstract Doc Link 16569376 Disease Relevance 0.98 Pain Relevance 0.15
Argatroban lacks major drug–drug interactions with CYP3A4/5 inhibitors such as erythromycin (Tran et al 1999) or with acetaminophen, warfarin, and digoxin (Brown and Hursting 2002; Inglis et al 2002).
CYP3A4 Binding (interactions) of associated with paracetamol
6) Confidence 0.47 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721302 Disease Relevance 0.22 Pain Relevance 0.10
The protein-protein interaction between CYP3A4 and UGT2B7 was further confirmed by overlay assay using glutathione S-transferase-CYP3A4 fusion protein.
CYP3A4 Binding (interaction) of
7) Confidence 0.46 Published 2005 Journal Mol. Pharmacol. Section Abstract Doc Link 15611481 Disease Relevance 0 Pain Relevance 0.45
Drugs that interact with CYP3A4 will not prevent conjugation, which is rate limiting.
CYP3A4 Binding (interact) of
8) Confidence 0.40 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682375 Disease Relevance 0.42 Pain Relevance 1.05
Buprenorphine interacts with CYP3A4 differently than methadone.
CYP3A4 Binding (interacts) of associated with methadone and buprenorphine
9) Confidence 0.40 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682375 Disease Relevance 0.42 Pain Relevance 1.01
Compared to reversible inhibition, mechanism-based inhibitors of CYP3A4 more frequently cause unfavorable drug-drug interactions, as the inactivated CYP3A4 has to be replaced by newly synthesized CYP3A4 protein.
CYP3A4 Binding (interactions) of
10) Confidence 0.37 Published 2004 Journal Curr. Drug Metab. Section Abstract Doc Link 15544435 Disease Relevance 0.09 Pain Relevance 0.17
CYP3A4 is known to metabolize a large variety of compounds varying in molecular weight from lidocaine (Mr = 234) to cyclosporine (Mr = 1203) (Guengerich 1999; Rendic 2002).
CYP3A4 Binding (metabolize) of associated with lidocaine
11) Confidence 0.37 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661603 Disease Relevance 0 Pain Relevance 0.10
In some instances, proper dose adjustment or alternative drugs may be needed when a CYP3A4 inactivator is combined with another drug.
CYP3A4 Binding (combined) of
12) Confidence 0.37 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661603 Disease Relevance 0.61 Pain Relevance 0.08
These include reversible inhibition of CYP3A by diltiazem and its metabolites, interactions of diltiazem with its metabolites, change of plasma protein binding, and possible involvement of drug transporters such as PgP.
CYP3A Neg (inhibition) Spec (possible) Binding (inhibition) of in plasma
13) Confidence 0.37 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661603 Disease Relevance 0.06 Pain Relevance 0.03
Irreversible inhibition of CYP3A4 due to enzyme inactivation or complexation occurs when some therapeutic drugs are converted by CYPs to reactive metabolites capable of covalently binding to CYP3A4 protein or heme moiety.
CYP3A4 Binding (binding) of
14) Confidence 0.37 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661603 Disease Relevance 0 Pain Relevance 0.04
The study of interactions of newly synthesized compounds with CYP3A4 has been incorporated into drug development and detection of possible CYP3A4 inhibitors and inducers during the early stages of drug development is critical in preventing potential drug-drug interactions and side effects.
CYP3A4 Binding (interactions) of
15) Confidence 0.37 Published 2008 Journal Curr. Drug Metab. Section Abstract Doc Link 18473749 Disease Relevance 0.15 Pain Relevance 0.12
Recently, there has been a greater appreciation of the potential drug interactions between CYP3A4 inhibitors and corticosteroid medications including topical steroid preparations.
CYP3A4 Binding (interactions) of
16) Confidence 0.37 Published 2010 Journal Pain Med Section Body Doc Link 20456080 Disease Relevance 0 Pain Relevance 0
The ratio [dinor-LAAM/(nor-LAAM plus dinor-LAAM)] with microsomes and CYP3A4 decreased with increasing LAAM concentration, suggesting most dinor-LAAM is formed from released nor-LAAM that subsequently reassociates with CYP3A4.
CYP3A4 Binding (reassociates) of
17) Confidence 0.37 Published 2001 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 11259570 Disease Relevance 0 Pain Relevance 0.03
Based on these results, we conclude that LAAM and nor-LAAM are predominantly metabolized by CYP3A4 in human liver microsomes, and CYP3A4 exhibits unusual multisite kinetics.
CYP3A4 Binding (metabolized) of in liver
18) Confidence 0.37 Published 2001 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 11259570 Disease Relevance 0 Pain Relevance 0.03
Possible interactions with CYP2D6 inhibitors (amiodarone, fluoxetine or ritonavir) and CYP3A4 inhibitors (indinavir and ritonavir) can increase its serum concentrations and produce significant adverse effects.
CYP3A4 Binding (interactions) of associated with fluoxetine
19) Confidence 0.37 Published 2002 Journal Clin Neuropharmacol Section Abstract Doc Link 12410055 Disease Relevance 0.63 Pain Relevance 0.13
A pharmacokinetic interaction between ciprofloxacin and the patient's comedication carbamazepine is unlikely to be the responsible mechanism, since fluoroquinolones inhibit cytochrome P450 isoenzyme CYP1A2 but not CYP3A4 which metabolizes carbamazepine.
CYP3A4 Binding (metabolizes) of
20) Confidence 0.36 Published 2009 Journal Int J Clin Pharmacol Ther Section Body Doc Link 19281725 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox